LTL Pharma was established by Unison Capital Group in August 2016,
and started its operation by sequentially succeeding 16 ethical drug products from Astellas Pharma Inc.
In addition to manufacturing and marketing of the ethical drugs in Japan,
LTL Pharma operates overseas business in alliance with the local partners in 16 countries.
Tetsuo Ito, President, Representative Director
Junko Katayanagi, Director
Naoki Kigawa, Director
Heuigon Song, Auditing Officer
Jiro Mizukawa
3-minute walk from Exit 2 of Nishi-Shinjuku station of Marunouchi line